Why Pomdoctor Limited’s (POM) Stock Is Down 7.45%
As of Thursday, November 19, Pomdoctor Limited’s POM share price has dipped by 7.45%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Cynthia McLaughlin
| Share Statistics | POM | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $61.0 | $1,721.2 | 19% |
|
| Shares Out (Mil) | 0.3 | 80.6 | 2% |
|
| Institutional Ownership | 0.0% | 87.6% | 0% |
|
| Float (Mil) | na | 59.2 | na |
|
| Beta | na | 0.74 | na |
|
| Avg Daily Volume (000s) | 82 | 613 | 33% |
|
| Price Change (52-week) |
na | 74.5% | na |
|
| Growth | POM | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 21.5% | 10.4% | 83% |
|
| Net Income (5yr) | 5.0% | (0.5%) | 48% |
|
| EPS (5yr) | (6.4%) | 3.0% | 24 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 15.9% | (17.4%) | 74% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | POM | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $60 | $1,529 | 21% |
|
| Net Income (TTM) (Mil) | ($55) | $33 | 15% |
|
| EPS (TTM) | ($30.071) | $0.300 | 2% |
|
| Operating Cash Flow (TTM) (Mil) | ($18) | $175 | 16% |
|
| Net Cash Flow (TTM) (Mil) | $1 | $7 | 48% |
|
| Long-Term Debt (Q1) (Mil) | $55 | $419 | 39% |
|
| Enterprise Value (Q1) (Mil) | $62 | $2,427 | 19% |
|
| Valuation | POM | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.56 | na |
|
| P/E | na | 25.9 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | POM | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 12.0% | 27.3% | 11% |
|
| Net Margin | (90.2%) | 1.4% | 8% |
|
| ROA | (628.7%) | 2.4% | 0% |
|
| ROE | 27.6% | 7.3% | 86% |
|
| Liabilities to Assets | 764.9% | 62.3% | 100% |
|
| F-Score | 2 | 5 | 7% |
|
Pomdoctor Limited did not pass any screens on 11/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors